Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Standard Biotools (LAB) Long-Term Investments (2025)

Historic Long-Term Investments for Standard Biotools (LAB) over the last 7 years, with Q3 2025 value amounting to $19.5 million.

Standard Biotools' Long-Term Investments changed N/A to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year change of. This contributed to the annual value of $6.5 million for FY2015, which is 7638.82% down from last year.
Latest data reveals that Standard Biotools reported Long-Term Investments of $19.5 million as of Q3 2025.
Standard Biotools' Long-Term Investments' 5-year high stood at $19.5 million during Q3 2025, with a 5-year trough of $19.5 million in Q3 2025.